CNIO and Highlight Therapeutics test a compound against the most common skin cancer (VIDEO)
Caption
Marisol Soengas, head of the Melanoma Group at the Spanish National Cancer Research Centre (CNIO), and Marisol Quintero, former Director of Innovation at the CNIO and current CEO of Highlight Therapeutics, explain the new clinical trial to demonstrate the efficacy of the compound BO-112 against basal cell carcinoma, one of the most common tumors. Results from the CNIO Melanoma Group led to the creation of the Spanish company Highlight Therapeutics, which has developed the compound BO-112. BO-112 is the first oncology drug candidate generated from CNIO research that has reached patient studies, demonstrating activity against various types of cancer. Basal cell carcinoma is the most common skin cancer; it is related to sun exposure and its incidence is increasing. It is a public-private partnership project funded with almost three million euros by the Ministry of Science, Innovation and Universities
Credit
Scienseed / CNIO
Usage Restrictions
Only to be used in the context of this feature story
License
Original content